These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 12774067)

  • 41. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 42. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design.
    Cagigi A; Nilsson A; De Milito A; Chiodi F
    Vaccine; 2008 Jun; 26(24):3016-25. PubMed ID: 18164520
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in T-cell subpopulations during four years of suppression of HIV-1 replication in patients with advanced disease.
    Lepej SZ; Begovac J; Vince A
    FEMS Immunol Med Microbiol; 2006 Apr; 46(3):351-9. PubMed ID: 16553807
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Battling the enemy on many fronts: inside the science of HIV vaccine development.
    Talley A; Chang S
    Body Posit; 2004; 17(4):8-12. PubMed ID: 15929208
    [No Abstract]   [Full Text] [Related]  

  • 45. Perspectives for a protective HIV-1 vaccine.
    Schiavone M; Quinto I; Scala G
    Adv Pharmacol; 2008; 56():423-52. PubMed ID: 18086420
    [No Abstract]   [Full Text] [Related]  

  • 46. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
    Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
    Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Simpler tests for immune cells could transform AIDS care in Africa.
    Willyard C
    Nat Med; 2007 Oct; 13(10):1131. PubMed ID: 17917650
    [No Abstract]   [Full Text] [Related]  

  • 48. Candidate vaccines for immunotherapy in HIV.
    Gotch FM; Imami N; Hardy G
    HIV Med; 2001 Oct; 2(4):260-5. PubMed ID: 11737407
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low CD4 T-cell counts despite low levels of circulating HIV: insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease.
    Albuquerque AS; Foxall RB; Cortesão CS; Soares RS; Doroana M; Ribeiro A; Lucas M; Antunes F; Victorino RM; Sousa AE
    Clin Immunol; 2007 Oct; 125(1):67-75. PubMed ID: 17692571
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.
    Grant P; Taylor J; Cain P; Short W; Gallant J; Farthing C; Thal G; Coakley E; Zolopa A
    Clin Infect Dis; 2009 Mar; 48(5):680-2. PubMed ID: 19191657
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD4+ T-cell subsets: what really counts in preventing HIV disease?
    Mason RD; De Rose R; Kent SJ
    Expert Rev Vaccines; 2008 Mar; 7(2):155-8. PubMed ID: 18324885
    [No Abstract]   [Full Text] [Related]  

  • 52. Vaccines for HIV--Remune returns.
    TreatmentUpdate; 2004 Oct; 16(6):3. PubMed ID: 17219678
    [No Abstract]   [Full Text] [Related]  

  • 53. Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development.
    Betts MR; Gray CM; Cox JH; Ferrari G
    Expert Rev Vaccines; 2006 Aug; 5(4):505-16. PubMed ID: 16989631
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CD4+ T cell receptor repertoire perturbations in HIV-1 infection: association with plasma viremia and disease progression.
    Malhotra U; Huntsberry C; Holte S; Lee J; Corey L; McElrath MJ
    Clin Immunol; 2006 Apr; 119(1):95-102. PubMed ID: 16403675
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Shift of CMV-specific CD4+ T-cells to the highly differentiated CD45RO-CD27- phenotype parallels loss of proliferative capacity and precedes progression to HIV-related CMV end-organ disease.
    Bronke C; Jansen CA; Westerlaken GH; De Cuyper IM; Miedema F; Tesselaar K; van Baarle D
    Clin Immunol; 2007 Aug; 124(2):190-9. PubMed ID: 17556025
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HIV management update.
    Hamada OL
    Am Fam Physician; 1997 Dec; 56(9):2186, 2188. PubMed ID: 9402807
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
    AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eager Thailand takes on questionable therapies.
    Birmingham K
    Nat Med; 2002 Aug; 8(8):767-8. PubMed ID: 12152015
    [No Abstract]   [Full Text] [Related]  

  • 60. A selection of trends in HIV research.
    Bean P
    Am Clin Lab; 2001 Jul; 20(6):12-4. PubMed ID: 11480386
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.